Financial Performance Expectations - The company expects a net loss of between 63 million and 82 million yuan for the fiscal year 2025, compared to a profit of 9.351 million yuan in the same period last year[3]. - The net profit after deducting non-recurring gains and losses is projected to be a loss of between 59 million and 77 million yuan, down from a profit of 3.304 million yuan year-over-year[3]. - Basic earnings per share are expected to be a loss of between 0.1391 yuan and 0.1810 yuan, compared to earnings of 0.0206 yuan per share in the previous year[3]. Operational Insights - The company’s operating revenue remains stable, but increased operational costs have led to a decline in overall gross margin due to intensified competition in the global consumer electronics industry[5]. - The company reported sequential and year-over-year growth in operating revenue in the fourth quarter, indicating a trend of gradual improvement in performance[5]. Future Strategies - Future strategies will focus on optimizing product structure and enhancing global operational efficiency to improve profitability and operational quality[6]. - The financial data presented is preliminary and subject to confirmation in the company's 2025 annual report[7].

证券代码：300510 证券简称：金冠股份 公告编号：2026-001 吉林省金冠电气股份有限公司 2025 年度业绩预告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、本期业绩预计情况 1、业绩预告期间：2025 年 1 月 1 日至 2025 年 12 月 31 日。 2、业绩预告情况：预计净利润为负值 3、信用减值损失。部分应收款项回收不及预期，基于谨慎性原则，对可能发生的 减值损失计提相应减值准备。 | 项 目 | | 本报告期 | | 上年同期 | | --- | --- | --- | --- | --- | | 归属于上市公司股东的净利润 | -36,000 | ～ | -30,000 | -33,300.24 | | 扣除非经常性损益后的净利润 | -38,000 | ～ | -32,000 | -35,475.73 | | 营业收入 | 105,000 | ～ | 108,000 | 108,377.94 | | 扣除后营业收入 | 100,000 | ～ | 103,000 | 104,188.18 | 二、与会计师事务所沟通情况 本 ...

证券代码：300472 证券简称：*ST 新元 公告编号：2026-016 万向新元科技股份有限公司 2、业绩预告情况：股票交易已被实施财务类退市风险警示后的首个会计年度、预计净利润为负值 （1）以区间数进行业绩预告的 单位：万元 | 项 目 | | 本会计年度 | | 上年同期 | | --- | --- | --- | --- | --- | | 利润总额 | -42,000 | ～ | -30,000 | -38,788.89 | | 归属于上市公司股东的净利润 | -42,569 | ～ | -30,569 | -44,152.53 | | 扣除非经常性损益后的净利润 | -41,274 | ～ | -29,274 | -46,419.39 | | 营业收入 | 12,183 | ～ | 14,183 | 13,074.1 | | 扣除后营业收入 | 12,000 | ～ | 14,000 | 12,756.07 | | 项 目 | | 本会计年度末 | | 上年末 | | 归属于上市公司股东的所有者权益 | 4,000 | ～ | 6,000 | 2,669.61 | 2025 年度业绩预告 本公司 ...

| 证券代码：300567 | 证券简称：精测电子 | 公告编号：2026-012 | | --- | --- | --- | | 债券代码：123176 | 债券简称：精测转2 | | 武汉精测电子集团股份有限公司 2025年度业绩预告 公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、本期业绩预计情况 1、业绩预告期间：2025 年 1 月 1 日至 2025 年 12 月 31 日 2、预计的业绩：□亏损 扭亏为盈 □同向上升 □同向下降 | 项目 | 本报告期 | 上年同期 | | --- | --- | --- | | 归属于上市 公司股东的 | 盈利：8,000 万元—9,000 万元 | 亏损：9,759.85 万元 | | 净利润 | 比上年同期增长：181.97%—192.21% | | | 扣除非经常 性损益后的 | 盈利：2,165.70 万元—3,165.70 万元 | 亏损：15,856.12 万元 | | 净利润 | 比上年同期增长：113.66%—119.97% | | 二、与会计师事务所沟通情况 公司半导体前道量测领域膜厚系列产 ...

2025 年年度业绩预告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 债券代码：127017 债券简称：万青转债 债券代码：524330 债券简称：25 江泥 01 江西万年青水泥股份有限公司 三、业绩变动原因说明 报告期内，受房地产和基础设施投资增速放缓等因素影响，水泥市场需 求整体收缩，行业供需关系更趋失衡，市场竞争日趋激烈。面对严峻的外部 环境，公司积极推进精益管理与"三基"建设，持续优化生产运营，并加大 资产处置与盘活力度，有效推动了生产成本的下降。然而，受产品销售价格 下行影响，成本降幅未能完全抵消价格下滑带来的压力，导致公司扣除非经 常性损益后的净利润出现亏损。2025 年预计与搬迁补偿相关的非经常性损益 对归属于上市公司股东的净利润影响约 1.6 亿元至 2.2 亿元，最终归属于上 市公司股东的净利润约 2350 万元至 3500 万元。 一、本期业绩预计情况 1、业绩预告期间：2025 年 1 月 1 日至 2025 年 12 月 31 日。 2、业绩预告情况：预计净利润为正值且属于同向上升 50%以上情形 （1）以区间数进行业绩预告的 单 ...

一、本期业绩预计情况 证券代码：002951 证券简称：金时科技 公告编号：2026-003 1、业绩预告期间：2025 年 1 月 1 日至 2025 年 12 月 31 日。 四川金时科技股份有限公司 2025 年度业绩预告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 | 项 | 目 | 本报告期 | | 上年同期 | | | --- | --- | --- | --- | --- | --- | | 归属于上市公司股 | | -28,000 | ～ | -23,000 | -439.7 | | 东的净利润 | | | | | | | 扣除非经常性损益 | | -28,200 | ～ | -23,200 | -6,279.42 | | 后的净利润 | | | | | | | 基本每股收益（元/ | | -0.69 | ～ | -0.57 | -0.01 | | 股） | | | | | | | 营业收入（如适 | | 40,000 | ～ | 44,500 | 37,581.99 | | 用） | | | | | | 2.储能行业项目回款周期较长，报告 ...

Financial Performance - The company expects a net loss attributable to shareholders of between 55 million and 38 million yuan, a decrease in loss of 4.01% to 33.68% compared to the previous year's loss of 57.2978 million yuan [4]. - The projected operating revenue is between 315 million and 350 million yuan, reflecting a change of -0.08% to -11.02% compared to the previous year's revenue of 315.2604 million yuan [4]. - The company anticipates a net loss after deducting non-recurring gains and losses of between 68 million and 54 million yuan, which is a change of -20.13% to -4.60% from the previous year's loss of 56.6055 million yuan [4]. - Basic earnings per share are expected to be a loss of between 0.0581 yuan and 0.0401 yuan, showing a reduction in loss of 3.97% to 33.72% compared to the previous year's loss of 0.0605 yuan per share [4]. Business Strategy - The company is focusing on deepening its core business and expanding market reach, with ongoing efforts to enhance its marketing network and service capabilities [6]. - Strategic investments and market channel development are expected to provide a solid foundation for the company's operational management in the upcoming year [6]. Financial Reporting - The financial data presented is preliminary and has not been audited, with the final figures to be confirmed in the official 2025 annual report [7].

证券代码：000815 证券简称：美利云 公告编号：2026-006 中冶美利云产业投资股份有限公司 2025年度业绩预告 本公司及董事会全体成员保证信息披露的内容真实、准 确、完整，没有虚假记载、误导性陈述或重大遗漏 | 项 目 | 本报告期 | 上年同期 | | --- | --- | --- | | | 2025 年 1 月 1 日-12 月 31 日 | 2024 年 1 月 1 日-12 月 31 日 | | 归属于上市公司 股东的净利润 | 盈利：5,100 万元-7,600 万元 | 亏损：54,848 万元 | | 扣除非经常性损 益后的净利润 | 盈利：5,600 万元-8,400 万元 | 亏损：6,421 万元 | | 基本每股收益 | 盈利：0.07 元/股-0.11 元/股 | 亏损：0.79 元/股 | 报告期内，公司关停清算造纸业务，有效减少亏损。同 时开展精益运营与成本管控，盈利能力得到提升。 2.预计的经营业绩：扭亏为盈 二、与会计师事务所沟通情况 本次业绩预告相关的财务数据为公司财务部门初步测 算结果，未经会计师事务所审计。公司就本次业绩预告与会 计师事务所进行了预沟通，双 ...

Financial Projections - The company expects to achieve an annual revenue of approximately 562 million yuan in 2025, representing a year-on-year increase of 35.75 million yuan, or 6.79%[4]. - The projected net loss attributable to shareholders for 2025 is estimated to be between 55 million and 82 million yuan, a decrease of 7.93 million to 34.93 million yuan compared to the previous year, reflecting a decline of 16.85% to 74.22%[4]. - The expected net loss attributable to shareholders after deducting non-recurring gains and losses is estimated to be between 112 million and 139 million yuan, a decrease of 18.32 million to 45.32 million yuan compared to the previous year, indicating an increase in loss of 19.56% to 48.38%[4]. - The previous year's net loss attributable to shareholders was 47.07 million yuan, with a net loss of 93.68 million yuan after deducting non-recurring gains and losses[6]. R&D and Expenses - The company has increased its R&D investment and expanded its product matrix, achieving a gross margin of approximately 43% despite intensified market competition[9]. - The total R&D and sales expenses have increased by approximately 13.5% compared to the previous year, contributing to the decline in profits[9]. - The company incurred share-based payment expenses of approximately 30 million yuan in 2025, which, when excluded, results in a projected net loss of between 25 million and 52 million yuan, roughly in line with the previous year[9]. Performance Forecast and Risks - The company emphasizes that the performance forecast is based on preliminary estimates and has not been audited by certified public accountants[10]. - Investors are advised to pay attention to investment risks as the forecast data is subject to change pending the official audited annual report[11].

Financial Performance - The company expects a net profit attributable to shareholders of the parent company to be between -85 million yuan and -66 million yuan for the year 2025[2]. - The net profit attributable to shareholders after deducting non-recurring gains and losses is projected to be between -84 million yuan and -65 million yuan[2]. - In the same period last year, the net profit attributable to shareholders was -54.42 million yuan, indicating a decline in performance year-over-year[3]. Research and Development - The company has increased its R&D investment in areas such as RNA drugs, antibody drugs, gene and cell therapy, organoids, and synthetic biology to strengthen its technological advantages[3]. - The company emphasizes its commitment to innovation and market expansion as part of its long-term growth strategy[3]. Marketing and Sales - Sales expenses have increased as the company expands its marketing team and enhances brand marketing efforts to capture more market share[4]. Government Subsidies and Income - The company has experienced a decrease in government subsidies compared to the same period last year, impacting other income[4]. Tax and Financial Reporting - The company has adjusted the value of deferred tax assets based on a cautious principle, leading to an increase in deferred tax expenses[4]. - The financial data provided is preliminary and has not been audited by registered accountants, highlighting the need for caution among investors[5]. - The final audited financial data will be disclosed in the 2025 annual report, and investors are advised to be aware of investment risks[6].